Loading...
Ertapenem, a recently developed and FDA-approved member of the carbapenem class of antibiotics, has a narrower spectrum of activity than other class members (for example, imipenem and meropenem). In this respect, it more closely resembles a third-generation cephalosporin such as ceftriaxone. Because the long serum half-life of ertapenem, like that of ceftriaxone, allows once daily dosing, it could be an alternative agent in clinical situations -- such as community-acquired pneumonia (CAP) -- in which ceftriaxone is commonly used. In a worldwide study sponsored by ertapenem's manufacturer, 383 adult patients with CAP who lacked comorbidities that might predispose them to a worse outcome received either 1 g of intravenous ceftriaxone or ertap…